Skip to main content

Table 3 Treatment outcome (n = 40, 100%)

From: To coagulate, ligate, or both: a randomized study comparing the safety and efficacy of two endoscopic approaches for managing gastric antral vascular ectasia in cirrhotic patients

Comparative factors Group I: combined therapy group Group II: EBL group P value
Mean/count %/±SD Mean/count %/±SD
Treatment sessions
 Mean number of treatment sessions 3.25 ± 1.07 1.95 ± 0.76 0.001*
 Mean number of banding sessions 1.5 ± 1.5 1.95 ± 0.76 0.034*
 Mean bands number used 8.3 ± 3.53 11.35 ± 5.44 0.042*
 Recurrence of bleeding from GAVE (after 6 months of follow-up) 3 15% 2 10% 0.676
 Cessation of bleeding (after 6 months of follow-up) 17 85% 18 90%  
Treatment outcomes      
 Hemoglobin (g/dl) at baseline 6.86 ± 1.25 7.71 ± 1.66 0.074
 Hospitalization at baseline 1.60 ± 1.00 1.50 ± 1.05 0.641
 Blood transfusion at baseline 3.90 ± 2.55 3.20 ± 2.24 0.360
 Hemoglobin (g/dl)(6 months follow-up) 9.78 ± 1.68 10.04 ± 1.93 0.646
 Hospitalization (6 months follow-up) 0.40 ± 0.88 0.40 ± 0.82 0.794
 Bood transfusion (6 months follow-up) 0.70 ± 1.98 0.95 ± 1.88 0.462
 The mean changes in hemoglobin (g/dl) 2.92 ± 1.50 2.33 ± 1.74 0.258
 The mean changes in hospitalization -1.2 ± 1.24 − 1.10 ± 0.91 0.773
 The mean changes in transfusion -3.20 ± 2.28 − 2.25 ± 1.52 0.130
  1. Unless otherwise stated numerical data are expressed as mean (SD). Statistically significant values are in bold
  2. P > 0.05 = not significant, *P < 0.05 = significant, **P < 0.01 = highly significant. Baseline transfusion and hospitalization applies to the last 6 months preceding recruitment